BRENTWOOD, Tenn.--(BUSINESS WIRE)--PathGroup, one of the largest private providers of anatomic pathology and clinical lab services in the U.S., today announced a new partnership with the Centers for Disease Control and Prevention (CDC) and the California Department of Public Health that standardizes nationwide state cancer registry data and reporting, enabling physicians, surgeons and researchers to make data-driven treatment decisions with real-time information and analyses.
Facilitated by the North American Associates of Central Cancer Registries, the partnership standardizes data collection with PathGroup’s laboratory information systems and guides users through the electronic Cancer Checklist, published by the College of American Pathologists, to improve the structure and integrity of state cancer registry data. This standardization allows cancer treatment specialists and patients to benefit from accurate, up-to-date data for therapeutic recommendations based on national trends and insights.
“Big data isn’t just a buzzword in health care – it’s foundational. With more than 15 million cancer patients in the U.S., it’s crucial for scientists and physicians to have access to the most comprehensive patient information possible,” said Dr. Ben Davis, president and CEO of PathGroup. “Leveraging our national reach and our mission to provide the highest quality pathology and clinical lab services, we’re proud to work with the CDC to set a new standard for informed cancer reporting, treatment and research.”
The CDC requires each state to maintain a cancer registry as part the National Program of Cancer Registries (NPCR). Because states vary in system design, reporting processes and data entry methods, it can be difficult for clinicians and researchers to identify patient trends or evaluate the effectiveness of recommended treatments.
By working with the CDC to nationally standardize data collection, PathGroup is engaging laboratory information system vendors, pathologists and laboratories to structure their own systems and generate actionable, real-time intelligence.
“Company-wide, we’re gathering massive amounts of clinically useful data for cancer patients every day,” said Dr. Derek Welch, chief medical officer of anatomic pathology for PathGroup. “Standardizing this data will give health care experts the statistical power they need to advance treatment and management of various malignancies, and as we continue rolling out data-driven reporting with more partners, we improve the opportunity for enhanced outcomes.”
Originally designed in cooperation with the California Department of Public Health, which recognized PathGroup’s national experience and leadership in clinical pathology and its technical expertise with laboratory structured data and reporting, PathGroup’s standards are now in place in 15 states, with more expected in the coming years.
PathGroup, a Pritzker Group company, currently works with more than 70 hospitals and thousands of group practices across the U.S. to deliver quality lab and diagnostics results with unmatched responsiveness. Founded in 1965 and led by physicians, PathGroup has more than 80 in-house pathology experts and more than 1,100 lab technicians dedicated to improving patient outcomes through high-quality service and direct physician contact.
Founded in 1965, PathGroup is a premier provider of anatomic, clinical and molecular pathology services, as well as one of the largest providers of women’s health services in the United States. Privately held and physician-centric, PathGroup works seamlessly with customers to provide superior diagnostic services – a vital link in the cycle of patient relationships. PathGroup uses the latest in proprietary and industry standard technology to deliver fast, accurate results. The company provides clients with the highest quality of services available, consistently exceeding the expectations of physicians, employees, payers and most importantly, patients. One Lab; Total Service. For more information, visit pathgroup.com.
About Pritzker Group
Pritzker Group, led by Tony and J.B. Pritzker, has three principal investment teams: Private Capital, which acquires and operates leading North America-based companies; Venture Capital, which provides early-stage and growth venture funding to technology companies throughout the United States; and Asset Management, which partners with top-performing investment managers across global public markets.
Pritzker Group Private Capital acquires North America-based middle-market companies with leading positions in the manufactured products, services and healthcare sectors. The firm’s permanent, proprietary capital base allows for efficient decision making, broad flexibility with transaction structure and investment horizon, and alignment with management teams focused on creating long-term value. Pritzker Group brings significant resources, expertise and credibility in building businesses and is an ideal partner for entrepreneur- and family-owned companies. For more information, visit pritzkergroup.com.